Menu Close

23 Senior Speakers Including Roche, Bupa, Ipsen, Merck & Pfizer Take To The Stage In 1 Day At The Patient Centricity & Engagement Conference

Secure Better Patient & Business Outcomes With Actionable, Tangible, Value-Adding Strategies To Enhance Patient Centricity & Engagement & Embed Patients At The Heart Of Decision Making
Collaborative Engagement & Experience Strategies Which Inform Clinical Trial Design, Drug Development & Strategic Business Direction With Early Patient Involvement, Insights & Feedback, Leverage Digital & Technology Innovations Compliantly & Enhance Patient Safety & Journey. A One-Day Conference & Networking Event, 21st May 2019, The Hallam Conference Centre, Central London

08:30 Registration, Morning Coffee & Objective Setting

09:00 GIC Welcome & Morning Chair’s Opening Remarks

Okan Ekinci
Chief Medical Officer
Roche

EMBEDDING PATIENTS AT THE HEART OF DECISION MAKING

09.15 Truly Embedding Patient Centricity Into Business Decision Making With Meaningful Patient Involvement For Tangibly Enriched Patient & Business Outcomes

  • Recognising the gaps between intent and action: taking a good look at internal strategies to determine where increased patient input can make the most impact on patient outcomes and commercial success; bring the patient voice into the organisation
  • Demonstrating a financial payoff to further motivate internal departments to involve patients in decision making and convince them of the importance of patient-pharma collaboration
  • How can we overcome industry hurdles such as tight regulations, communications barriers and internal apathy to deliver real examples of commitment, change and tangible outputs as well as a commitment to progress and more meaningful patient involvement?

Jeffrey Wren
Executive Vice President, Neurology Patient Value Head
UCB

EARLY PATIENT INVOLVEMENT

09.35 Clinical Trial Design & Drug Development: Recruit & Action Patient Feedback On Trial Design For More Effective R&D & Better Patient Outcomes & Experiences

  • Innovative methods of creating awareness and recruiting patients into early-stage R&D for crucial patient feedback which improves trial experience and effectiveness
  • Bridging the gap between patients, industry and stakeholder insights and needs and real-world evidence for meaningful, multi-stakeholder drug development processes
  • Practical steps to feed patient-reported outcomes and insights into development strategies which build patient value into design
  • Closing the loop – how can pharma brands build a community and better relay the outcomes of a clinical trial to the patient volunteers?
Vertical---Speaker 18.03

09.35 Perspective One:

Marisol Urbieta
Oncology Medical Affairs Head
AstraZeneca

09.55 Perspective Two:

David Rich
Vice President, Clinical Development, Rare Diseases, Global R&D
Ipsen

THE PATIENT PERSPECTIVE - Q&A PANEL

10.15 The Patient Perspective: What Can Pharma Do To Enable More Meaningful & Effective Patient-Pharma Collaboration?

  • Pharma want to know how they can better create awareness, engage patients and feed patient feedback into the decision making of the company. What do you think they should be doing differently?
  • The patient point of view – what in the system do you want to challenge and what do you and the patient community expect from the pharma industry?
  • The future: how do you think long-term pharma-patient relationships could be improved? What measures would you like to see put in place?

Alison Doyle
Clinical & Operations Director
National Osteoporosis Society

Sara Osborne
Head of Patient Communication & Involvement
Cancer Research

Michael Chekroun
CEO and Founder
Carenity

Simon Nicholls
Global Product Director (Customer Labs)
Bupa

Lea-Isabelle Proulx
Patient Insights Leader
Roche

 

10.45 Morning Refreshment Break With Informal Networking

Breakout Groups By Therapy Area:

A: Cancer Care
B: Mental Health
C: Long-Term Conditions
D: Rare Diseases
E: Diabetes
F: Other Breakouts By Area

PATIENT & PHARMA COLLABORATION CASE STUDY - Q&A PANEL

11.15 Our Story: Real-Life Patient-Pharma Collaboration – Overcoming Barriers For Meaningful, Value-Adding Relationships Which Positively Impact Patient Outcomes & Pharma’s Bottom Line

  • How our relationship started: from initial contact to long-term partnership, how did our relationship evolve and what helped it flourish?
  • How did we enable this collaboration to be effective? What did we both need and how did we overcome hurdles and manage expectations to align our shared objectives?
  • Who else did we need? From third parties, regulatory boards and HCPs, how did we motivate and involve the right people?
  • What have we achieved? Evidence of value created for patients, the healthcare system and pharma

Vanessa Pott
Director, Patient Advocacy & Strategic Partnerships

Merck

PLUS! Patient Partner Speaker To Be Confirmed

CASE STUDY

11.35 Leveraging Technology For Optimal Patient Engagement

  • Learn about innovative, technological solutions that can be implemented in order to eliminate patient engagement barriers
  • Discuss the use of these tools that foster learnings, deeper insights, and more timely feedback
  • Explore real world case studies

Peter Gannon
SVP Business Partnerships
Within3

COLLABORATION WITH KEY STAKEHOLDERS - INSIGHTS PANEL

12.05 Exploring Blockers To Multi-Stakeholder Collaboration: How Can We All Align Behind The Patient?

There are many reasons why it can be difficult to have meaningful patient input within pharma. This panel is bringing together key stakeholders within the industry to explore how multi-stakeholder collaboration can be approached more efficiently to uncover tangible ways of moving forwards together.

Liesbeth De Boer-Oosterhuis
Manager Alliance Development & Patient Advocacy

Pfizer

Jill Pearcy
Director
ABPI Code Engagement

Further speakers to be announced. Please check the website for further details.

12.35 Lunch For Speakers, Delegates & Partners

13.05 Informal Peer-To-Peer Discussion Zones

A) Patient Experience

Dr Mate A. Balazs
Country Head - Patient Safety
Novartis

B) Patient Advocacy Group Perspective - Clinical Trials

Dr Helen Bulbeck
Director of Services & Policy

Brainstrust - the brain cancer people

Stephen Nabarro
Head of Clinical Operations & Data Management, Centre for Drug Discovery

Cancer Research

C) Pharma Perspective - Patient Experience & Clinical Trial Design

Lea-Isabelle Proulx
Patient Insights Leader
Roche

D) HCPS

E) Patient Recruitment

13.35 Afternoon Chair’s Opening Remarks

Paul Edwards
Director of Clinical Services
Dementia UK

ENHANCING PATIENT JOURNEYS, INFORMATION & FEEDBACK - CASE STUDY

13.50 Challenges In Providing Accurate Information To Patients, With An Insight Into Data Use

  • How are patients seeking information? What tools are out there today to handle patient data and information to provide the best possible experiences?
  • Innovative and effective methodologies to collect accurate patient data and translate patient feedback and data into actionable insights to improve patient services
  • What should change to significantly improve the value and quality of clear information to patients?

Krzysztof Wojciechowski
Public Policy & Patient Engagement Director, Europe, Russia, Africa, Middle East
MSD

PATIENT ENGAGEMENT THROUGH DIGITAL & TECH - DOUBLE PERSPECTIVE

14.10 Leveraging New Technologies Compliantly To Improve Patient Experience For Interactive Communications Which Engage Patients Around Their Healthcare

  • Exploring the potential impact and long-term implications of new technologies on patient care: what are the innovations we need to sit up and listen to, what do patients want and how can we make a real difference with quite simple tech and tools?
  • Applying digital channels and technologies to enhance patient recruitment, increase patient engagement through clinical trials and accessing information about their treatment
  • Identifying opportunities new tech offers to collect valuable and intangible data such as emotions, reactions side effects, adverse event reporting and ineffective drugs during trials and with drugs on the market
  • Exploring the implications of the HTA reform

14:10 Perspective One

Nathalia Figueiredo
Consumer Planning & Insights
Walgreens Boots Alliance

14:30 Perspective Two

Isabel Torres
VP Market Access, Public A airs & Patient Advocacy, Europe & Canada

Takeda

14.55 Bonus Session Reserved For Exclusive Conference Partner. For more information on how to get involved, please call +44 (0) 20 3479 2299 or email partner@patientengagementconference.com

15.25 Afternoon Refreshment Break With Informal Networking

VALUE-ADDING PATIENT EXPERIENCES

15.50 Determining The Impact Of Patient-Pharma Collaboration & Value Added To The Patient & The Business

  • How do you tangibly measure value-added? How do you measure how valuable and effective patient engagement is?
  • Patient reported outcomes - what do patients consider value adding?
  • Creating value is great – but, how can you create value at scale?

Geoff Rollason
Patient Experience & Service Director
Pfizer

PATIENT SAFETY

16.10 Significant Measures Pharma Can Take To Further Ensure Patient Safety Throughout The Patient Journey

  • Ensuring it is patient safety at the forefront of decision making
  • Refining your patient safety strategies in the real world where increased complexities, comorbidities and other drugs ramp up the chances of an adverse reaction
  • Better engaging and communicating with the patient around their treatment by using technologies to educate them on reporting and their own conditions
  • Understanding and consulting on patient preference and going beyond patient experience to decide risk-reward profiles

16.10 Perspective One
James Whitehead

Principal, Pharmacovigilance Processes & Partnerships
AstraZeneca

OVERCOMING BARRIERS TO PATIENT CENTRICITY

16.50 It’s All Very Well Talking The Talk But How Can Pharma Actually Take Steps To Progress Their Patient Strategies, Improve Patient Outcomes & Further The Business?

How can you overcome barriers to:

  • Health-check your own activities and ensure your organisation is really patient-centric - then readdress strategies if necessary?
  • Adapt to different patient behaviours, engagement and motivation levels?
  • Enhance patient communications and engage better with the patient on decision making?
  • Successfully execute initiatives in view of regulation?

Sara Osborne
Head of Patient Communication & Involvement
Cancer Research

Paul Robinson
European Lead, Patient Innovation

MSD

Isabela Niculae
Associate Director Global Patient Recruitment & Retention Strategist

Biogen

Heather Moses
Head of Medical Affairs Oncology

Roche

17.00 Co-Chairs’ Closing Remarks & Official Close Of Conference